1 May 2011BiotechAshley Roughton

Patenting life

Our European patent system is self-financing, self-sufficient and almost self-legislating. It works on two, intertwined levels. It is complex, has its own courts, and perhaps, some may say, the very last thing we need is further legislative interest by a body that, until recently, has had little to do with patenting in Europe. Yet this is what the European Council and Parliament did when trying to legislate for patents and morality in 1998 via Directive 98/44/EC on the legal protection of biotechnological inventions—the Biotech Directive.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
3 September 2026   Turnaround for 10x after Federal Circuit setback as Delaware jury finds Qiagen-owned Parse infringed three patents covering single-cell sequencing technology.
Biotech
1 September 2026   Judges dismissed an appeal from MSN Laboratories, which was hoping to show that several patents covering Cabometyx were invalid and would not be infringed by its generic product.
Biotech
31 August 2026   Efforts to shut down an eight-patent dispute over cancer-detection technology have run into a hurdle in a Delaware federal court.